# Importer of Controlled Substances Application: Fisher Clinical Services, Inc.
**AGENCY:**
Drug Enforcement Administration, Justice.
**ACTION:**
Notice of application.
**SUMMARY:**
Fisher Clinical Services, Inc. has applied to be registered as an importer of basic class(es) of controlled substances. Refer to Supplemental Information listed below for further drugs information.
**DATES:**
Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before October 19, 2020. Such persons may also file a written request for a hearing on the application on or before October 19, 2020.
**ADDRESSES:**
Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.
**SUPPLEMENTARY INFORMATION:**
In accordance with 21 CFR 1301.34(a), this is notice that on August 3, 2020, Fisher Clinical Services, Inc., 7554 Schantz Road, Allentown, Pennsylvania 18106-9032, applied to be registered as an importer of the following basic class(es) of controlled substances:
| Controlled | Drug | Schedule |
| --- | --- | --- |
| Psilocybin | 7437 | I |
| Methylphenidate | 1724 | II |
| Levorphanol | 9220 | II |
| Noroxymorphone | 9668 | II |
| Tapentadol | 9780 | II |
The company plans to import the listed controlled substances for clinical trials only.
Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of the Food and Drug Administration approved or non-approved finished dosage forms for commercial sale.
William T. McDermott,
Assistant Administrator.